A5102888072- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Occupational and environmental lung diseases
- Epigenetics and DNA Methylation
- Blood Pressure and Hypertension Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Testicular diseases and treatments
- Peptidase Inhibition and Analysis
- Immune cells in cancer
- Gut microbiota and health
- Viral-associated cancers and disorders
- Meta-analysis and systematic reviews
- Pleural and Pulmonary Diseases
- Inflammatory Biomarkers in Disease Prognosis
- Radiation Therapy and Dosimetry
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
Chinese Academy of Medical Sciences & Peking Union Medical College
2020-2025
Northwest A&F University
2023
Molecular Oncology (United States)
2020-2022
State Key Laboratory of Molecular Oncology
2020-2022
National Clinical Research
2022
Sichuan University
2018-2020
West China Hospital of Sichuan University
2019
Pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) continues to carry a high burden in terms of mortality. With the roles gut microbiota mediating lung diseases being gradually uncovered, details molecular mechanism "gut-lung axis" mediated beneficial microorganisms and small-molecule metabolites have attracted attention researchers. However, further studies are still necessary determine efficacy microbial-based interventions. Our findings indicate that sodium butyrate...
The high heterogeneity of tumour and the complexity microenvironment (TME) greatly impacted development prognosis cancer in era immunotherapy. In this study, we aimed to portray single cell-characterised landscape lung adenocarcinoma (LUAD), develop an integrated signature incorporating both TME for stratification.
Abstract Despite the central role of human leukocyte antigen class I (HLA-I) in tumor neoantigen presentation, quantitative determination presentation capacity remains elusive. Based on a pooled pan-cancer genomic dataset 885 patients treated with immune checkpoint inhibitors (ICIs), we developed score integrating binding affinity neoantigens to HLA-I, as well HLA-I allele divergence, termed HLA tumor-Antigen Presentation Score (HAPS). Patients high HAPS were more likely experience survival...
Objectives: Previous studies have reported the prognostic value of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte (PLR), lymphocyte/monocyte (LMR), and systemic immune-inflammation index (SII). However, performance these indices in patients with testicular lymphoma has not yet been studied. This study was to systematically evaluate role NLR, PLR, LMR, SII predicting survival for diffuse large B-cell lymphoma. Methods: In this study, 28 were enrolled. We performed univariate...
Pappalysin 2 (PAPPA2) mutation, occurring most frequently in skin cutaneous melanoma (SKCM) and non-small cell lung cancer (NSCLC), is found to be related anti-tumour immune response. However, the association between PAPPA2 efficacy of checkpoint inhibitors (ICIs) therapy remains unknown.To analyse performance mutation as an indicator stratifying beneficiaries ICIs, seven public cohorts with whole-exome sequencing (WES) data were divided into NSCLC set (n = 165) SKCM 210). For further...
Molecular indicators of long-term survival (LTS) in response to immune-checkpoint inhibitor (ICI) treatment have the potential provide both mechanistic and therapeutic insights. In this study, we construct predictive models LTS following ICI therapy based on data from 158 clinical trials involving 21,023 patients 25 cancer types with available 1-year overall (OS) rates. We present evidence for use OS rate as a surrogate LTS. Based these corresponding TCGA multi-omics data, total neoantigen,...
Dear Editor, Identifying reliable biomarkers for immune checkpoint inhibitors (ICIs) can efficiently screen beneficiaries to improve their clinical use. We developed a public web server, IMPACT, facilitate the comprehensive investigation of predictive or prognostic biomarkers, interaction effects and biological mechanisms with both in-house datasets (http://www.brimpact.cn/ http://impact.brbiotech.com/) (Figure 1A). ICIs have heralded new era in cancer treatment, while most ICI low...
Abstract By employing bibliometric method, this study aimed to visualize the research hotspots and correlations among clinical medicine subjects. Literatures were retrieved from PubMed database based on MeSH words free-text phrases screened inclusion exclusion criteria. The disease themes manually marked according ICD-10. Co-word analysis strategic diagram methods applied explore hot topics development trends of themes. 2551 articles included after literature screening. amount paper showed...
Introduction: Recent studies exhibited the unstable prediction ability of blood-based tumor mutational burden (bTMB) when predicting response immune checkpoint inhibitors (ICIs) therapy in patients with non-small cell lung cancer (NSCLC). Circulating DNA (ctDNA) abundance, usually represented by maximum somatic allele frequency (MSAF), was one possible confounding factor influencing bTMB ICIs prediction. Methods: MSAF-adjusted (Ma-bTMB) established and validated advanced NSCLC among Geneplus...
Fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron-emission tomography/computed tomography (PET/CT), a hybrid imaging technique that simultaneously provides functional and anatomical information, has been reported to be useful in lymphoma. The present study was evaluate the parameters of F-FDG PET/CT patients with testicular diffuse large B-cell lymphoma (DLBCL). We retrospectively reviewed medical records 5095 who treated at West China Hospital between March 2003 January 2017, selected...
Summary Immune checkpoint inhibitors (ICIs) are a breakthrough in oncology treatment, and studies of screening predictive biomarkers ICIs emerging. We developed web server named IMPACT ( http://impact.brbiotech.com/ ) to thoroughly explore immunotherapeutic or prognostic biomarkers. contains large dataset 6,276 patients treated with integrates 11 well-designed function modules, enabling an in-depth solution for exploration. Compared the existing tools, was implemented one exclusive module...
Abstract Background With the improvement of therapeutic strategies from cytotoxic chemotherapy to immunotherapy, possibility achieving timely intervention for lung cancer has dramatically increased. This study aimed systematically evaluate reporting quality randomized controlled trials (RCT) on immunotherapy in cancer. Methods The RCTs evaluating efficacy published up 2021 were searched and collected PUBMED EMBASE by two investigators. 2010 Consolidated Standards Test Reports (CONSORT)...
e20102 Background: Chemotherapy-induced myelosuppression (CIM) is the major dose-limiting and severe complication for chemotherapy, particularly etoposide plus platinum-based therapy (EP), in patients with extensive-stage small-cell lung cancer (ES-SCLC). CIM adversely affects patient quality of life imposes substantial economic burden. In China, there’s a scarcity related studies, especially large cohort. This study aims to summarize burden treatments ES-SCLC using nationally representative...
The molecular mechanisms underlying long-term survival benefits after immune-checkpoint inhibitor (ICI) treatment remain unclear. We determined the 1-year overall (OS) rate as a surrogate metric for ICI therapy via 132 clinical trials involving 17442 cancer patients receiving single ICI. cancer-specific outcomes and corresponding TCGA-derived multi-omics parameters were integrated to identify biomarkers; with each type regarded unit. Total neoantigen, metabolism score, CD8+ T cell, CXCL5...
e21137 Background: ctDNA abundance can influence the accuracy of blood-based tumor mutational burden (bTMB), driving a paradox bTMB in predicting response and survival benefit patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) therapy. However, optimal algorithm adjusted remains largely unestablished. We aimed to develop novel approach optimize calculation by integrating maximum somatic allele frequency (MSAF) better differentiate ICI-beneficial...
Abstract Backgroud: Tumor mutation burden (TMB) remains a promising but ambiguous biomarker for the efficacy of immune checkpoint inhibitors (ICIs)-based regimens. We conducted multifaceted systematic review and meta-analysis, public cohort validation, to provide pooled evidence prediction value TMB ICIs in advanced non-small cell lung cancer (NSCLC). Methods: Mirror-based meta-analysis balancing confounding factors was applied Part1, Bayesian network Part2. PubMed, Embase, Cochrane Central...